Oramed Phase 3 oral insulin trial fails; discontinues T2D program

ORAMED PHARMACEUTICALS INC.

Phase 3 ORA-D-013-1 of ORMD-0801 missed primary endpoint: mean A1C change at 26 weeks.
Secondary endpoint (fasting plasma glucose) also missed; no serious drug-related adverse events.
Company will discontinue all oral insulin clinical activities for type 2 diabetes.

item 8.01

ORAMED PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-002343

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.